Open access
Sep 2026
Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition
Inhibiting pan-RAS(on) RAS-GTP with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.
Michael P. East, J. Olivares-Quintero, D. Okumu et al.
· bioRxiv · 0 citations